Micromedic Identified New Generic Markers to Predict Risk of Developing BRONJ, a Devastating Side Effect of Certain Cancer Drugs


Micromedic Technologies (TASE: MCTC) has identified several new genetic markers with high potential to predict necrosis of the jawbone in multiple myeloma patients treated with bisphosphonate drugs.  Upon confirmation of the findings, Micromedic plans to develop a diagnostic assay for use with multiple myeloma and perhaps other patients.

Link to complete article

More News/Information
© Micromedic Technologies Ltd. site mapcontact
Site by Site2goal | Design Studio Michal Lehavi